{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:51:32Z","timestamp":1774450292879,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) such as pembrolizumab have revolutionized the treatment of advanced melanoma, but many patients do not respond to ICIs alone, and thus there is need for additional treatment options. Topical immunomodulators such as diphencyprone (DPCP) also have clinical use in advanced melanoma, particularly in the treatment of cutaneous metastases. In a previous report, we characterized the enhanced clinical response to dual agent immunotherapy with pembrolizumab and DPCP in a patient with cutaneous melanoma metastases. To improve mechanistic understanding of this response, we analyzed proteomic data using the Olink immuno-oncology panel of 96 biomarkers from tissue and serum samples of this patient throughout his treatment course. Particular attention was paid to programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and lymphocyte-activation gene 3 (LAG-3) given they are all targeted by ICIs in clinical practice. These proteins were upregulated during the period of DPCP monotherapy, then downregulated during pembrolizumab monotherapy, and then robustly upregulated again during dual therapy. Although not exclusively, the induction of checkpoint inhibitor proteins in the presence of DPCP suggests potential synergy between this agent and ICIs in the treatment of cutaneous melanoma metastases. Large-scale investigation is warranted to further evaluate this potential novel combination therapeutic approach.<\/jats:p>","DOI":"10.1038\/s41598-022-27020-1","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T10:02:44Z","timestamp":1672048964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment"],"prefix":"10.1038","volume":"12","author":[{"given":"Joseph","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneesh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade N.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayan","family":"Owji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen","family":"Luu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Poplausky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Yassky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeriel","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"key":"27020_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med. 50, 1\u201311 (2018).","journal-title":"Exp. Mol. Med."},{"key":"27020_CR2","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).","journal-title":"Nat. Commun."},{"key":"27020_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1590\/abd1806-4841.20187162","volume":"93","author":"IL Gibbons","year":"2018","unstructured":"Gibbons, I. L. et al. Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience. An Bras. Dermatol. 93, 299\u2013301 (2018).","journal-title":"An Bras. Dermatol."},{"key":"27020_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/exd.13030","volume":"25","author":"N Gulati","year":"2016","unstructured":"Gulati, N., Carvajal, R. D., Postow, M. A., Wolchok, J. D. & Krueger, J. G. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. Exp. Dermatol. 25, 553\u2013554 (2016).","journal-title":"Exp. Dermatol."},{"key":"27020_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.13229","volume":"43","author":"T Fujimura","year":"2016","unstructured":"Fujimura, T. et al. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports. J. Dermatol. 43, 686\u2013689 (2016).","journal-title":"J. Dermatol."},{"key":"27020_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1758834014567470","volume":"7","author":"R Sundar","year":"2015","unstructured":"Sundar, R., Cho, B.-C., Brahmer, J. R. & Soo, R. A. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther. Adv. Med. Oncol. 7, 85\u201396 (2015).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"27020_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/0284186X.2020.1712473","volume":"59","author":"JC Moser","year":"2020","unstructured":"Moser, J. C. et al. Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol. 59, 434\u2013437 (2020).","journal-title":"Acta Oncol."},{"key":"27020_CR8","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jid.2016.06.611","volume":"136","author":"N Gulati","year":"2016","unstructured":"Gulati, N. et al. Molecular profiling of immune activation associated with regression of melanoma metastases induced by diphencyprone. J. Invest. Dermatol. 136, 2101\u20132103 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"27020_CR9","first-page":"1546","volume":"9","author":"Y Ma","year":"2019","unstructured":"Ma, Y., Wang, Q., Dong, Q., Zhan, L. & Zhang, J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am. J. Cancer Res. 9, 1546\u20131553 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"27020_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3389\/fimmu.2020.00922","volume":"11","author":"JG Skeate","year":"2020","unstructured":"Skeate, J. G. et al. TNFSF14: LIGHTing the way for effective cancer immunotherapy. Front. Immunol. 11, 922 (2020).","journal-title":"Front. Immunol."},{"key":"27020_CR11","doi-asserted-by":"publisher","first-page":"33123","DOI":"10.1038\/srep33123","volume":"6","author":"KV Sawant","year":"2016","unstructured":"Sawant, K. V. et al. Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions. Sci. Rep. 6, 33123 (2016).","journal-title":"Sci. Rep."},{"key":"27020_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik, J. Nivolumab plus relatlimab: First approval. Drugs 82, 925\u2013931 (2022).","journal-title":"Drugs"},{"key":"27020_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","volume":"13","author":"A Antonelli","year":"2014","unstructured":"Antonelli, A. et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev. 13, 272\u2013280 (2014).","journal-title":"Autoimmun. Rev."},{"key":"27020_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584626","volume":"11","author":"F Antonangeli","year":"2020","unstructured":"Antonangeli, F. et al. Regulation of PD-L1 Expression by NF-\u03baB in Cancer. Front. Immunol. 11, 584626 (2020).","journal-title":"Front. Immunol."},{"key":"27020_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.seminoncol.2017.10.013","volume":"44","author":"F Alessandrini","year":"2017","unstructured":"Alessandrini, F., Pezz\u00e8, L. & Ciribilli, Y. LAMPs: Shedding light on cancer biology. Semin. Oncol. 44, 239\u2013253 (2017).","journal-title":"Semin. Oncol."},{"key":"27020_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","volume":"155","author":"J Jacobs","year":"2015","unstructured":"Jacobs, J. et al. CD70: An emerging target in cancer immunotherapy. Pharmacol. Ther. 155, 1\u201310 (2015).","journal-title":"Pharmacol. Ther."},{"key":"27020_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/jso.23506","volume":"109","author":"DL Damian","year":"2014","unstructured":"Damian, D. L., Saw, R. P. M. & Thompson, J. F. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J. Surg. Oncol. 109, 308\u2013313 (2014).","journal-title":"J. Surg. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-27020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-27020-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-27020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T11:19:15Z","timestamp":1672053555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-27020-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["27020"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-27020-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"17 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22364"}}